umdlavuza Colorectal
The researchers found that adding SIRT to chemotherapy can improve izinga lokusinda umdlavuza colorectal
New research shows that for patients with colorectal cancer who have only liver metastases or mainly liver metastases, adding selective in vivo radiotherapy based on standard first-line mFOLFOX6 chemotherapy can significantly increase the median overall survival time of patients with primary tumors on the right.
USolwazi Guy van Hazel waseNyuvesi YaseNtshonalanga Australia uthe: “Okutholakele kwethu kudinga ukuqinisekiswa okwengeziwe, ngakho-ke singacabangela izinketho zokusebenzisa kusenesikhathi ezigulini ezinezicubu zesibindi eziyinhloko ezinomdlavuza we-colon metastatic (mCRC) ezinama-metastases esibindi kuphela noma ikakhulukazi ama-metastases esibindi. I-Sexual in vivo radiotherapy (SIRT). “Wanezela:” Lokhu okutholakele kuyizindaba ezinhle ezigulini ezinamathumba angakwesokudla. Banokubikezelwa okubi kakhulu kanye nezinketho zokwelashwa ezimbalwa kuneziguli ezinamathumba angakwesokunxele. “
Indawo yesimila esiyinhloko se-mCRC iyisici esibalulekile sokubikezela kanye nesibikezelo sempendulo yokwelashwa. Isibonelo, ucwaningo lwango-2016 lubonise ukuthi iziguli ezinamathumba ayisisekelo ohlangothini lwesokudla zinempendulo empofu kanye ne-prognosis kuneziguli ezinezimila eziyinhloko ohlangothini lwesobunxele.
Ukuhlola ukusebenza kahle nokuphepha kwe-SIRT
I-SIRT iwuhlobo lwe-in vivo radiotherapy ye-Y-90 resin microspheres, elawulwa nge-intrahepatic artery catheter. I-Beta radiation microspheres ifinyelela ngokukhethekile ohlelweni lwe-microvascular eduze kwesimila, olunganciphisa imiphumela yesistimu.
Izifundo zomhlaba wonke ze-SIRFLOX, FOXFIRE kanye ne-FOXFIRE zasetshenziselwa ukuhlola ukusebenza kahle nokuphepha kwe-oxaliplatin-based chemotherapy yomugqa wokuqala kanye ne-SIRT ye-mCRC engalungiseki. Ekuhlaziyeni okuhlangene, iziguli ezingama-554 zithole ukwelashwa ngamakhemikhali kanye ne-SIRT, futhi iziguli ezingama-549 zithole ukwelashwa ngamakhemikhali kuphela. Isikhathi esimaphakathi sokusinda sisonke sasiyizinyanga ezingama-22.6 nezingu-23.3, ngokulandelana. Ekuhlaziyweni kokuhlolwa kwesidumbu, indawo yesimila esiyinhloko yatholwa cishe efomini lombiko wecala leqembu. Isimila esingakwesokudla sachazwa njenganoma isiphi isimila esiyinhloko ekugcineni okuseduze kwe-splenic flexure, futhi isimila esingakwesobunxele sachazwa njenganoma yisiphi isimila ku-splenic flexure, kude nekholoni noma isimila Esiyinhloko ku-rectum.
I-SIRT plus chemotherapy ingandisa isikhathi sokusinda
Imiphumela yabonisa ukuthi isikhathi esimaphakathi sokusinda kweziguli ezine-mCRC ezishiye izimila kwakuyizinyanga ezingama-24.6 eqenjini le-chemotherapy kanye ne-SIRT, kanye nezinyanga ezingama-26.6 eqenjini le-chemotherapy kuphela. Kodwa-ke, isikhathi esimaphakathi sokusinda seziguli zesimila esilungile se-mCRC kwakuyizinyanga ezingama-22 eqenjini le-chemotherapy kanye ne-SIRT, kanye nezinyanga eziyi-17.1 eqenjini le-chemotherapy kuphela. Ukuhlolwa kwezibalo okujwayelekile komthelela wokwelashwa kusikhathi sonke sokusinda ngendawo nakho kufakazela ukuthi uhlangothi lwesimila lubaluleke kakhulu.
One hypothesis is that right-sided tumors not only have a poorer prognosis, they are more resistant to chemotherapy, and may be more sensitive to radiation therapy with a completely different mechanism of action.
Ukuntuleka kwemiphumela emihle ekuhlaziyeni jikelele kungase kube ngenxa yokufakwa kweziguli ezine-extrahepatic tumor metastases. Nakuba i-SIRT ingakwazi ukulawula ukuphazamiseka kwesibindi, ayikwazi ukulawula ukuphazamiseka kwe-extrahepatic.
